治疗人类表皮生长因子受体 2 低表达和人类表皮生长因子受体 2 高表达转移性乳腺癌的新方法。

IF 2.2 4区医学 Q2 OBSTETRICS & GYNECOLOGY

Current Opinion in Obstetrics & Gynecology Pub Date : 2024-02-01 Epub Date: 2023-12-07 DOI:10.1097/GCO.0000000000000930

Karissa Britten, Nicholas McAndrew

{"title":"治疗人类表皮生长因子受体 2 低表达和人类表皮生长因子受体 2 高表达转移性乳腺癌的新方法。","authors":"Karissa Britten, Nicholas McAndrew","doi":"10.1097/GCO.0000000000000930","DOIUrl":null,"url":null,"abstract":"Purpose of review: In recent years, there has been a flurry of activity in the human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer space. New, powerful drugs like trastuzumab deruxtecan have challenged our fundamental definition of what HER2 expression means as a predictive biomarker.Recent findings: Recent approvals of multiple agents in the second line-metastatic setting have given patients access to a variety of new agents, but also raise questions with regard to optimal sequencing.Summary: This review will explore current issues with HER2 testing, recently approved drugs in the HER2+ and HER2 low spaces, as well as novel agents/combinations on the horizon.","PeriodicalId":55194,"journal":{"name":"Current Opinion in Obstetrics & Gynecology","volume":"36 1","pages":"34-39"},"PeriodicalIF":2.2000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"New approaches for human epidermal growth factor receptor 2-low and human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.\",\"authors\":\"Karissa Britten, Nicholas McAndrew\",\"doi\":\"10.1097/GCO.0000000000000930\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose of review: In recent years, there has been a flurry of activity in the human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer space. New, powerful drugs like trastuzumab deruxtecan have challenged our fundamental definition of what HER2 expression means as a predictive biomarker.Recent findings: Recent approvals of multiple agents in the second line-metastatic setting have given patients access to a variety of new agents, but also raise questions with regard to optimal sequencing.Summary: This review will explore current issues with HER2 testing, recently approved drugs in the HER2+ and HER2 low spaces, as well as novel agents/combinations on the horizon.\",\"PeriodicalId\":55194,\"journal\":{\"name\":\"Current Opinion in Obstetrics & Gynecology\",\"volume\":\"36 1\",\"pages\":\"34-39\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Opinion in Obstetrics & Gynecology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/GCO.0000000000000930\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/12/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Obstetrics & Gynecology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/GCO.0000000000000930","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

综述的目的：近年来，人表皮生长因子受体 2（HER2）阳性转移性乳腺癌领域的研究活动层出不穷。曲妥珠单抗（trastuzumab）、德鲁克斯替康（deruxtecan）等新型强效药物挑战了我们对HER2表达作为预测性生物标志物的基本定义：摘要：本综述将探讨 HER2 检测目前存在的问题、HER2+ 和 HER2 低表达领域最近批准的药物以及即将上市的新型药物/组合。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

New approaches for human epidermal growth factor receptor 2-low and human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.

Purpose of review: In recent years, there has been a flurry of activity in the human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer space. New, powerful drugs like trastuzumab deruxtecan have challenged our fundamental definition of what HER2 expression means as a predictive biomarker.

Recent findings: Recent approvals of multiple agents in the second line-metastatic setting have given patients access to a variety of new agents, but also raise questions with regard to optimal sequencing.

Summary: This review will explore current issues with HER2 testing, recently approved drugs in the HER2+ and HER2 low spaces, as well as novel agents/combinations on the horizon.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current Opinion in Obstetrics & Gynecology 医学-妇产科学

CiteScore

4.10

自引率

0.00%

发文量

104

审稿时长

6-12 weeks

期刊介绍： Current Opinion in Obstetrics and Gynecology is a bimonthly publication offering a unique and wide ranging perspective on the key developments in the field. Each issue features hand-picked review articles from our team of expert editors. With eleven disciplines published across the year – including reproductive endocrinology, gynecologic cancer and fertility– every issue also contains annotated references detailing the merits of the most important papers.